August 22, Hangzhou, China — Luca Healthcare and SANTO Biotech (Hangzhou) Co., Ltd. have entered into a strategic partnership to co-develop cutting-edge AI-powered digital health technologies (DHT) for clinical applications in cell and gene therapies, including CAR-T, TCR-T, gene therapy, and gene editing.
This collaboration will focus on integrating remote monitoring and patient-centric data capture into clinical development workflows, while jointly building and validating AI capabilities for early detection of high-risk safety events—specifically Cytokine Release Syndrome (CRS) and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS). The goal is to elevate patient safety, streamline trial operations, and enhance the quality of clinical evidence.
SANTO Biotech is a trailblazer in in vivo gene therapy, leveraging proprietary next-generation lentiviral vector technologies. With over 20 years of expertise in vector engineering and disease mechanism research, the company has contributed extensively to top-tier scientific publications. Its three core platforms—the 5G Vector Delivery System, Animal Disease Modeling Platform, and Process Optimization Platform—form a robust, self-sustaining biotech ecosystem. SANTO is focused on developing transformative therapies for high-burden conditions such as neurofibromatosis, meningioma, and malignant mesothelioma, and is actively working to integrate gene therapies into national reimbursement frameworks.
In vivo CAR-T therapy represents a rapidly advancing frontier in oncology and immunotherapy. Despite its therapeutic promise, it is frequently associated with serious adverse events—including CRS, ICANS, hematologic toxicities, and opportunistic infections—stemming from T-cell activation, cytokine surges, and immune system disruption. Early prediction, real-time monitoring, and precision intervention are essential to mitigating these risks and optimizing clinical outcomes.
Through this alliance, Luca Healthcare and SANTO Biotech will harness AI to build predictive safety models and dynamic risk management tools for in vivo CAR-T therapies, aiming to redefine clinical control and maximize patient benefit.
“AI and in vivo CAR-T are converging to shape the future of precision medicine. We’re honored to partner with Luca Healthcare to deliver safer, smarter therapeutic solutions for cancer patients worldwide,” said Dr. Lu Zhou, CEO of SANTO Biotech.
“We’re excited to collaborate with SANTO Biotech on this transformative journey. CAR-T therapy is a cornerstone of next-generation oncology, and our vision for AI-powered digital biomarkers and disease management is deeply aligned. Together, we aim to accelerate innovation and unlock new hope for patients,” said Dr. Echo Chen, CEO of Luca Healthcare.